#United States #New York #Pomerantz LLP #Encompass Health #EHC

Investor Alert: Pomerantz Law Firm Investigates Encompass Health Corporation

Pomerantz LLP, a leading firm specializing in corporate and securities litigation, has initiated an investigation on behalf of investors of Encompass Health Corporation, which trades under the ticker symbol EHC on the NYSE. This inquiry arises from serious allegations that may indicate unlawful business practices, including securities fraud by Encompass and its upper management.

The investigation has gained traction following a troubling article published in The New York Times on July 15, 2025. The piece cited federal inspection data that revealed for-profit hospitals owned by Encompass Health consistently fall short in key safety benchmarks. Specifically, the report highlighted that many of these hospitals have worse-than-average rates regarding preventable readmissions, including 34 facilities that received negative ratings from Medicare for their higher than acceptable rates of such readmissions. Additionally, the article alarmingly described multiple incidents involving critical errors that led to the unfortunate deaths of patients under the care of Encompass’s facilities.

In the wake of the publication, Encompass Health's stock suffered a significant decline, dropping $12.39 per share—a staggering 10.35%—to close at $107.28 on that same day. This downturn has raised substantial concerns about the long-term implications for the company and its investors.

Pomerantz LLP, which operates in major cities like New York, Chicago, and Los Angeles, is recognized for its history of advocating for investors' rights and pursuing accountability in corporate conduct. With over 85 years of experience, the firm has prominently recovered numerous substantial damages on behalf of those affected by securities fraud and corporate misconduct.

As the investigation progresses, it’s crucial for investors seeking further information or wishing to participate in a class action lawsuit to reach out to Danielle Peyton at Pomerantz LLP via email or phone. This case is drawing considerable attention not only due to the allegations but also because it highlights significant issues within the healthcare industry related to patient safety and corporate ethics.

Investors are advised to stay informed about the ongoing developments regarding Encompass Health Corporation and to consider the potential ramifications that these findings could have on their investments. The commitment of firms like Pomerantz to fight for shareholder rights remains fundamental in navigating the complexities of corporate governance and accountability in today’s market.

For more detailed updates and information, potential class members can refer to Pomerantz’s official website, where additional resources and links for joining the class action are available.